Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 24:11:966.
doi: 10.3389/fphar.2020.00966. eCollection 2020.

Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy

Ying Wang  1 , Yang Zhang  2 , Qian Yu  1 , Kun Zhu  1
Affiliations

Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy

Ying Wang et al. Front Pharmacol. .

Abstract

Given the extreme importance of the current pandemic caused by COVID-19 and due to the fact that scientists agree that there is no identified treatment, this paper analyzes in detail the treatment of a severe COVID-19 patient with convalescent plasma and drugs based on current guidelines for COVID-19 diagnosis and treatment. This can provide a reference for other medical institutions on rational drug use and pharmaceutical care for severe COVID-19 patients.

Keywords: COVID-19 (severe); convalescent plasma; drugs analysis; guideline; therapeutic strategy.

PubMed Disclaimer

References

    1. Ahrens I., Schwarz M., Peter K., Bode C. (2007). Therapeutic Inhibitors of Platelet Aggregation ?from Aspirin to Integrin Blockersf. Transfus. Med. Hemother. 34 (1), 44–54. 10.1159/000097664 - DOI
    1. Arabi Y. M., Hajeer A. H., Luke T., Raviprakash K., Balkhy H., Johani S., et al. (2016). Feasibility of Using Convalescent Plasma Immunotherapy for MERSCoV Infection, Saudi Arabia. Emerg. Infect. Dis. 22 (9), 1554–1561. 10.3201/eid2209.151164 - DOI - PMC - PubMed
    1. Beigel J. H., Tebas P., Elie-Turenne M. C., Bajwa E., Bell T. E., Cairns C. B., et al. (2017). Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study [published correction appears in Lancet Respir Med. Lancet Respir. Med. 5 (6), 500–511. 10.1016/S2213-2600(17)30174-1 - DOI - PMC - PubMed
    1. Bian Y., Yang Z. Y., Xiong Y., Tong R. S., Yan J. F., Long E. W., et al. (2020). Discussion on clinical pharmaceutical service model in prevention and treatment of corona virus disease 2019. Chin. J. New Drugs Clin. Rem. 39 (04), 212–217. 10.14109/j.cnki.xyylc.2020.04.05 - DOI
    1. Bulgakova V. A., Poromov A. A., Grekova A. I., Pshenichnaya Y. N., Selkova E. P., Lvov N. I., et al. (2017). Pharmaco-epidemiological study of the course of influenza and other acute respiratory viral infections in risk groups. Ter. Arkh. 89 (1), 62–71. 10.17116/terarkh201789162-71 - DOI - PubMed

LinkOut - more resources